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Supplemental fig. 1 
 
 
Rate of performed primary percutaneous coronary intervention (PCI) related to cancer therapy and entity showing 












Supplemental fig. 2  
 
 
Five year all-cause mortality of cancer patients divided in advanced and non-advanced cancer with troponin 
positive acute coronary syndrome (trop. pos./ STEMI and NSTEMI) or troponin negative angina (trop. neg./ 
unstable and stable angina).  Patients with advanced cancer presented with trop. pos. ACS had the highest 












Supplemental table 1 
Baseline characteristics of cancer patients with troponin-positive acute coronary syndrome (trop. pos.) vs. 
troponin-negative angina (trop. neg.) 
 Cancer + 
Trop. neg.  
(n=77) 
Cancer +  
Trop. pos.  
(n=76) 
P value 
Age, years 67.1 (± 11.4) 64.42 (± 11.5) 0.160 
Male sex, n (%) 55 (71.4) 57 (75) 0.716 
BMI, kg/m² 26.4 (± 4.8) 25.6 (± 4.8) 0.300 
Vascular risk factors, n (%)    
 Diabetes mellitus 19 (24.7) 18 (23.7) 1.000 
 Smoking 30 (39.0) 32 (42.1) 0.743 
 Hypertension 63 (81.8 58 (76.3) 0.432 
 Dyslipidemia 37 (48.1) 37 (48.7) 1.000 
Medical history, n (%)    
 Coronary artery disease 32 (41.6) 24 (31.6) 0.241 
 Atrial fibrillation 23 (29.9) 16 (21.1) 0.266 
 PAOD 8 (10.4) 11 (14.5) 0.473 
 CAOD 2 (2.6) 6 (7.9) 0.167 
 Stroke 3 (3.9) 9 (11.8) 0.079 
 COPD 15 (19.5) 17 (22.4) 0.695 
Laboratory findings    
 Creatinine, mg/dl 1.03 (0.77-1.32) 1.08 (0.86-1.26) 0.900 
 GFR <60 ml/min/1.73m², n (%) 33 (42.9) 29 (38.2) 0.622 
 Hb, g/dl 11.1 (± 1.7) 10.6 (± 1.9) 0.300 
 Platelet count, /nl 221 (174-282) 215 (152-277) 0.600 
 Reduced EF (<40%), n (%) 11 (14.7) 16 (23.2) 0.207 
Medication history, n (%)    
 Acetylsalicylic acid 39 (50.6) 31 (40.8) 0.257 
 Dual antiplatelet therapy 11 (14.3) 4 (5.3) 0.100 
 Anticoagulation 8 (10.4) 6 (7.9) 0.780 
 Statin use 24 (31.2) 20 (26.3) 0.593 
 Beta-blockers 52 (67.5) 45 (59.2) 0.317 
BMI body mass index, PAOD peripheral artery occlusive disease, CAOD cerebral artery occlusive disease, 
COPD chronic obstructive pulmonary disease, GFR glomerular filtration rate, Hb hemoglobin, EF ejection 
fraction 




Supplemental table 2 
Results of cardiac catheter examinations in Cancer patients with troponin-positive acute coronary syndrome 
(trop. pos.) vs. troponin-negative angina (trop. neg.) 
 
CAD coronary artery disease, CTO chronic total occlusion, LMCA left main coronary artery, PCI percutaneous 
coronary intervention, DES drug eluting stent, BMS bare metal stent, SYNTAX SYNergy between PCI with 
TAXus and cardiac surgery, LVEDP left ventricular end-diastolic pressure 
Data is shown as median (IQR)  
*Statistically significant difference between Trop. neg. vs. Trop. pos. cancer patients  
†excluded patients with history for coronary artery bypass surgery, included: Cancer + Trop. neg. n=68, Cancer + 
Trop pos. n=67 
‡patients with performed PCI: Cancer + Trop. neg. n=21, Cancer + Trop pos. n=37 
§ documented LVEDP: Cancer + Trop. neg. n=57, Cancer + Trop pos. n=53 
 
 Cancer + 
Trop. neg.  
(n=77) 
Cancer + 
Trop. pos.  
(n=76) 
P value 
Findings, n (%)    
 Multivessel disease 37 (48.1) 44 (57.9) 0.258 
 Absence of CAD 26 (33.8) 18 (23.7) 0.212 
 CTO 11 (14.3) 18 (23.7) 0.154 
 LMCA stenosis 7 (9.1) 11 (14.5) 0.327 
 Culprit lesion 33 (42.9) 41 (53.9) 0.197 
 Small vessel disease 31 (40.3) 34 (44.7) 0.625 
 PCI (any) 25 (32.5) 37 (48.7) 0.049* 
 DES 12 (15.6) 26 (34.2) 0.009* 









 Lowest tertile (≤22), n (%) 
 Intermediate tertile (23-32) 
 Highest tertile (≥33) 
 Score post PCI‡ 
















LVEDP§, mmHg 13 (5.25-16) 15 (7-22.75) 0.158 
